More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings (-30.4% Growth)
- Ratings (4.1 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/29/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements
Licensing and royalty revenue
Total revenue 38.47M
Research and development
General and administrative 9.82M
Total operating expenses 87.4M
Loss from operations -48.93M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 1.47M
Interest expense -9.63M
Gain (loss) on investments, net
Loss before income tax expense
Income tax expense 231K
Net loss -56.86M
Basic net loss (in dollars per share) -0.47
Diluted net loss (in dollars per share) -0.47
Shares used in computing basic net loss per share (in shares) 120.8M
Shares used in computing diluted net loss per share (in shares) 120.8M